Arcutis Biotherapeutics is a commercial-stage dermatology company focused on inflammatory skin diseases. Its lead franchise is ZORYVE (roflumilast), a topical PDE4 inhibitor developed in cream and foam formulations for conditions such as plaque psoriasis, atopic dermatitis and seborrheic dermatitis. The strategy centers on non-steroidal topical therapies that can be used across body sites and patient groups often limited by traditional steroids or systemic drugs.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 81.5 | — | -15.9 | — |
| Q3 2025 | 99.2 | — | 7.4 | — |
| Q4 2025 | 129.5 | — | 17.4 | — |
| Q1 2026 | 105.4 | — | -11.3 | — |
| Q2 2026 | 129.9 | 59.3% | 15 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Telix Pharmaceuticals Limited (TLX), Academy Sports and Outdoors, Inc. (ASO), Legend Biotech Corporation (LEGN), Wingstop Inc. (WING), Freshworks Inc. (FRSH), Universal Display Corporation (OLED)